The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Infections Caused by Resistant Gram‐Negative Bacteria: Epidemiology and Management
Open accessAbstract
Infections caused by resistant gram‐negative bacteria are becoming increasingly prevalent and now constitute a serious threat to public health worldwide because they are difficult to treat and are associated with high morbidity and mortality rates. In the United States, there has been a steady increase since 2000 in rates of extended‐spectrum β‐lactamase–producing Enterobacteriaceae, carbapenem‐resistant Enterobacteriaceae, and multidrug‐resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii, particularly among hospitalized patients with intraabdominal infections, urinary tract infections, ventilator‐associated pneumonia, and bacteremia. Colonization with resistant gram‐negative bacteria is common among residents in long‐term care facilities (particularly those residents with an indwelling device), and these facilities are considered important originating sources of such strains for hospitals. Antibiotic resistance is associated with a substantial clinical and economic burden, including increased mortality, greater hospital and antibiotic costs, and longer stays in hospitals and intensive care units. Control of resistant gram‐negative infections requires a comprehensive approach, including strategies for risk factor identification, detection and identification of resistant organisms, and implementation of infection‐control and prevention strategies. In treating resistant gram‐negative infections, a review of surveillance data and hospital‐specific antibiograms, including resistance patterns within local institutions, and consideration of patient characteristics are helpful in guiding the choice of empiric therapy. Although only a few agents are available with activity against resistant gram‐negative organisms, two recently released β‐lactam/β‐lactamase inhibitor combinations – ceftolozane/tazobactam and ceftazidime/avibactam – have promising activity against these organisms. In this article, we review the epidemiology, risk factors, and antibiotic resistance mechanisms of gram‐negative organisms. In addition, an overview of treatment options for patients with these infections is provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Dellit, T. H., Owens, R. C., McGowan, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O., Carpenter, C. F., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510393 · Cited by 3,362
Bradford, P. A. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.933-951.2001 · Cited by 2,618
Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,044
Sievert, D. M., Ricks, P., Edwards, J. R., Schneider, A., Patel, J., Srinivasan, A., Kallen, A., Limbago, B., Fridkin, S., & National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities (2013) · Infection Control & Hospital Epidemiology · doi:10.1086/668770 · Cited by 1,582
Tzouvelekis, L. S., Markogiannakis, A., Psichogiou, M., Tassios, P. T., & Daikos, G. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05035-11 · Cited by 1,191
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139
Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis588 · Cited by 1,016
OXA-48-like carbapenemases: the phantom menace
Poirel, L., Potron, A., & Nordmann, P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks121 · Cited by 924
Tacconelli, E., Cataldo, M. A., Dancer, S. J., De Angelis, G., Falcone, M., Frank, U., Kahlmeter, G., Pan, A., Petrosillo, N., Rodríguez-Baño, J., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12427 · Cited by 864
Snitkin, E. S., Zelazny, A. M., Thomas, P. J., Stock, F., Program, N. C. S., Henderson, D. K., Palmore, T. N., & Segre, J. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004129 · Cited by 863
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Diversity, Epidemiology, and Genetics of Class D β-Lactamases
Poirel, L., Naas, T., & Nordmann, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01512-08 · Cited by 632
Daikos, G. L., Tsaousi, S., Tzouvelekis, L. S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., Stefanou, I., Sypsa, V., Miriagou, V., Nepka, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02166-13 · Cited by 597
Vital signs: carbapenem-resistant Enterobacteriaceae.
(2013) · PubMed Central · Cited by 531
Lodise, T. P., Lomaestro, B., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510590 · Cited by 527
Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens
Pfeifer, Y., Cullik, A., & Witte, W. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2010.04.005 · Cited by 494
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
Zhanel, G. G., Lawson, C. D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P. R. S., Denisuik, A., Rubinstein, E., Gin, A. S., Hoban, D. J., et al. (2013) · Drugs · doi:10.1007/s40265-013-0013-7 · Cited by 433
Lledo, W., Hernández, M., Lopez, E., Molinari, O. L., Soto, R. Q., Hernández, E., Vispo, N. S., Flores, M., Vázquez, G. J., Robledo, I. E., et al. (2009) · PubMed · Cited by 430
Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ097 · Cited by 420
Durante-Mangoni, E., Signoriello, G., Andini, R., Mattei, A., De Cristoforo, M., Murino, P., Bassetti, M., Malacarne, P., Petrosillo, N., Galdieri, N., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit253 · Cited by 405
Wagenlehner, F. M., Umeh, O., Steenbergen, J., Yuan, G., & Darouiche, R. O. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62220-0 · Cited by 388
Mauldin, P. D., Salgado, C. D., Hansen, I. S., Durup, D. T., & Bosso, J. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01041-09 · Cited by 360
Vardakas, K. Z., Tansarli, G. S., Rafailidis, P. I., & Falagas, M. E. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks301 · Cited by 354
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes
van Duin, D., Kaye, K. S., Neuner, E. A., & Bonomo, R. A. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.11.009 · Cited by 352
Self-citationExtended-spectrum β-lactamase-producing organisms
Falagas, M. E., & Karageorgopoulos, D. E. (2009) · Journal of Hospital Infection · doi:10.1016/j.jhin.2009.02.021 · Cited by 346
Zhanel, G. G., Chung, P., Adam, H., Zelenitsky, S., Denisuik, A., Schweizer, F., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Walkty, A., et al. (2014) · Drugs · doi:10.1007/s40265-013-0168-2 · Cited by 340
Clinical and economic burden of antimicrobial resistance
Maragakis, L. L., Perencevich, E. N., & Cosgrove, S. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.751 · Cited by 329
Zavascki, A. P., Carvalhaes, C. G., Picão, R. C., & Gales, A. C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.108 · Cited by 312
Doi, Y., Park, Y. S., Rivera, J. I., Adams-Haduch, J. M., Hingwe, A., Sordillo, E. M., Lewis, J. S., Howard, W. J., Johnson, L. E., Polsky, B., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis942 · Cited by 303
Kanj, S. S., & Kanafani, Z. A. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0674 · Cited by 269
Dalfino, L., Puntillo, F., Mosca, A., Monno, R., Spada, M. L., Coppolecchia, S., Miragliotta, G., Bruno, F., & Brienza, N. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis286 · Cited by 247
Sirijatuphat, R., & Thamlikitkul, V. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02435-13 · Cited by 235
Lucasti, C., Popescu, I., Ramesh, M. K., Lipka, J., & Sable, C. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks523 · Cited by 234
Lahiri, S. D., Mangani, S., Durand-Reville, T., Benvenuti, M., De Luca, F., Sanyal, G., & Docquier, J.-D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02247-12 · Cited by 230
Vazquez, J. A., González Patzán, L. D., Stricklin, D., Duttaroy, D. D., Kreidly, Z., Lipka, J., & Sable, C. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.748653 · Cited by 219
Farrell, D. J., Flamm, R. K., Sader, H. S., & Jones, R. N. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01802-13 · Cited by 203
The therapeutic monitoring of antimicrobial agents
Begg, E. J., Barclay, M. L., & Kirkpatrick, C. J. M. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00850.x · Cited by 200
ESBLs: A Clear and Present Danger?
Dhillon, R. H.-P., & Clark, J. (2012) · Critical Care Research and Practice · doi:10.1155/2012/625170 · Cited by 192
Landman, D., Bratu, S., Kochar, S., Panwar, M., Trehan, M., Doymaz, M., & Quale, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm129 · Cited by 192
Bad Bugs, No Drugs: No ESCAPE Revisited
Peterson, L. R. (2009) · Clinical Infectious Diseases · doi:10.1086/605539 · Cited by 187
Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients
Perez, F., & Van Duin, D. (2013) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.80a.12182 · Cited by 184
Treatment of Acinetobacter infections
Michalopoulos, A., & Falagas, M. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003596350 · Cited by 180
Aktaş, Z., Kayacan, C., & Oncul, O. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.09.012 · Cited by 169
Extended-Infusion Cefepime Reduces Mortality in Patients with Pseudomonas aeruginosa Infections
Bauer, K. A. A., West, J. E., O’Brien, J. M., & Goff, D. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02365-12 · Cited by 154
Sheng, W., Liao, C., Lauderdale, T.-L. Y., Ko, W., Chen, Y.-S., Liu, J.-W., Lau, Y.-J., Wang, L.-S., Liu, K.-S., Tsai, T.-Y., et al. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.02.2254 · Cited by 136
Multidrug‐Resistant Gram‐Negative Bacteria in a Long‐Term Care Facility: Prevalence and Risk Factors
Pop-Vicas, A. E., Mitchell, S. L., Kandel, R., Schreiber, R., & D’Agata, E. M. C. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01787.x · Cited by 135
Craig, W. A., & Andes, D. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01590-12 · Cited by 131
Cost of Gram-negative resistance*
Evans, H. L., Lefrak, S. N., Lyman, J. A., Smith, R. L., Chong, T. W., McElearney, S. T., Schulman, A. R., Hughes, M. G., Raymond, D. P., Pruett, T. L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000251496.61520.75 · Cited by 128
Carbapenem-resistantAcinetobacter baumannii: epidemiology, surveillance and management
Pogue, J. M., Mann, T., Barber, K. E., & Kaye, K. S. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.14 · Cited by 121
Self-citationChandorkar, G., Huntington, J. A., Gotfried, M. H., Rodvold, K. A., & Umeh, O. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks246 · Cited by 118
Bouchillon, S. K., Badal, R. E., Hoban, D. J., & Hawser, S. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.03.022 · Cited by 111
Zilberberg, M. D., & Shorr, A. F. (2013) · Journal of Hospital Medicine · doi:10.1002/jhm.2080 · Cited by 97
Hoffmann, M., DeMaio, W., Jordan, R. A., Talaat, R. E., Harper, D. M., Speth, J., & Scatina, J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015735 · Cited by 92
Trends in antimicrobial resistance in intensive care units in the United States
Prabaker, K. K., & Weinstein, R. A. (2011) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32834a4b03 · Cited by 88
Nguyen, H. M., Shier, K. L., & Graber, C. J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt450 · Cited by 81
Denkinger, C. M., Grant, A. D., Denkinger, M. D., Gautam, S., & D’Agata, E. M. C. (2012) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2012.05.006 · Cited by 80
Current Epidemiology of Multidrug-Resistant Gram-Negative Bacilli in the United States
Kallen, A. J., & Srinivasan, A. (2010) · Infection Control and Hospital Epidemiology · doi:10.1086/655996 · Cited by 70
Pop-Vicas, A. E., Tacconelli, E., Gravenstein, S., Lü, B., & D’Agata, E. M. C. (2009) · Infection Control and Hospital Epidemiology · doi:10.1086/596608 · Cited by 68
Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit
Maragakis, L. L. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181e6cbc5 · Cited by 64
Risk factors for nephrotoxicity onset associated with polymyxin B therapy
Dubrovskaya, Y., Prasad, N., Lee, Y., Esaian, D., Figueroa, D. A., & Tam, V. H. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv014 · Cited by 63
Marchaim, D., Chopra, T., Bogan, C., Bheemreddy, S., Sengstock, D. M., Jagarlamudi, R., Malani, A. N., Lemanek, L., Moshos, J. A., Lephart, P., et al. (2012) · American Journal of Infection Control · doi:10.1016/j.ajic.2011.09.011 · Cited by 59
Self-citationPogue, J. M., Mynatt, R. P., Marchaim, D., Zhao, J. J., Barr, V. O., Moshos, J. A., Sunkara, B., Chopra, T., Chidurala, S., & Kaye, K. S. (2013) · Infection Control and Hospital Epidemiology · doi:10.1086/674849 · Cited by 56
Self-citationDenys, G. A., Callister, S. M., & Dowzicky, M. J. (2013) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-12-24 · Cited by 52
Risk factors for carbapenem-resistant Gram-negative bacteremia in intensive care unit patients
Routsi, C., Pratikaki, M. E., Platsouka, E. D., Sotiropoulou, C., Papas, V., Pitsiolis, T., Tsakris, A., Nanas, S., & Roussos, C. (2013) · Intensive Care Medicine · doi:10.1007/s00134-013-2914-z · Cited by 49
Babinchak, T., Badal, R. E., Hoban, D. J., Hackel, M., Hawser, S., Lob, S. H., & Bouchillon, S. K. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.02.031 · Cited by 37
Cited by
Liao, S., Zhang, Y., Pan, X., Zhu, F., Jiang, C., Liu, Q., Cheng, Z., Dai, G., Wu, G., Wang, L., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s191340 · Cited by 499
Sartelli, M., Chichom-Mefire, A., Labricciosa, F. M., Hardcastle, T., Abu-Zidan, F. M., Adesunkanmi, A. K., Ansaloni, L., Bala, M., Balogh, Z. J., Beltrán, M. A., et al. (2017) · World Journal of Emergency Surgery · doi:10.1186/s13017-017-0141-6 · Cited by 494
Torres, A., Zhong, N., Pachl, J., Timsit, J.-F., Kollef, M., Chen, Z., Song, J., Taylor, D., Laud, P. J., Stone, G. G., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30747-8 · Cited by 441
Interference in Bacterial Quorum Sensing: A Biopharmaceutical Perspective
Rémy, B., Mion, S., Plener, L., Elias, M., Chabrière, E., & Daudé, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00203 · Cited by 332
Morris, S., & Cerceo, E. (2020) · Antibiotics · doi:10.3390/antibiotics9040196 · Cited by 287
Metadata
- Authors
- Kaye, K. S., & Pogue, J. M.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2015-10
- Volume
- 35
- Issue
- 10
- Pages
- 949-962
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2143952244
- Cited by
- 383
- References
- 69
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.